MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
24.49
+1.33 (5.74%)
Sep 26, 2024, 4:00 PM EDT - Market closed
MBX Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -47.2 | -32.56 | -26.14 |
| Depreciation & Amortization | 0.19 | 0.16 | 0.06 |
| Loss (Gain) From Sale of Assets | 0.07 | 0.07 | - |
| Loss (Gain) From Sale of Investments | -1.56 | -1.04 | -0.03 |
| Stock-Based Compensation | 4.16 | 2.04 | 0.31 |
| Other Operating Activities | 0.1 | 0.1 | 1.39 |
| Change in Accounts Payable | 1 | 0.41 | 0.67 |
| Change in Other Net Operating Assets | 0.39 | -1.15 | 0.62 |
| Operating Cash Flow | -42.85 | -31.98 | -23.12 |
| Capital Expenditures | -0.8 | -0.13 | -0.44 |
| Investment in Securities | -39.22 | -30.8 | -10.97 |
| Investing Cash Flow | -40.02 | -30.93 | -11.41 |
| Short-Term Debt Issued | - | - | 10 |
| Total Debt Issued | - | - | 10 |
| Net Debt Issued (Repaid) | - | - | 10 |
| Issuance of Common Stock | 0.28 | 0.74 | 0.03 |
| Other Financing Activities | -1.85 | -0.03 | -0.46 |
| Financing Cash Flow | 66.94 | 69.22 | 46.06 |
| Net Cash Flow | -15.94 | 6.31 | 11.53 |
| Free Cash Flow | -43.65 | -32.11 | -23.56 |
| Free Cash Flow Per Share | -3.10 | -2.62 | -2.94 |
| Levered Free Cash Flow | - | -20.56 | - |
| Unlevered Free Cash Flow | - | -20.56 | - |
| Change in Net Working Capital | - | 0.56 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.